BMY - Amgen says FDA declined full approval for lung cancer drug Lumakras
2023-12-26 09:29:27 ET
More on Amgen
- Amgen: Wonderful Stock At Decent Price
- Amgen: Bet On Its Breakthrough Drug
- Amgen Inc. (AMGN) Presents at 6th Annual Evercore ISI HealthCONx Conference (Transcript)
- Amgen upgraded by BMO on underappreciated opportunity in obesity/metabolic space
- Dividend Roundup: Alibaba, Amgen, AT&T, Southwest Airlines, and more
For further details see:
Amgen says FDA declined full approval for lung cancer drug Lumakras